The Online Investor
Daily M&A
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Mega-Mergers: Largest Recent M&A Transactions

By The Online Investor Staff, updated Tue., Mar. 31, 4:25 AM

Slide #1. Teva Pharmaceutical Industries Ltd. Auspex

Acquirer: Teva Pharmaceutical Industries Ltd. (TEVA)
Acquiree: Auspex (ASPX)
Details: Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Auspex Pharmaceuticals, Inc. (NASDAQ:ASPX), today announced that they have entered into a definitive merger agreement under which Teva will commence a tender offer for all of the outstanding shares of Auspex at $101.00 per share in cash, representing total consideration of approximately $3.2 billion in enterprise value and approximately $3.5 billion in equity value. This transaction is expected to enhance Teva's revenue and earnings growth profile and strengthen its core central nervous system (CNS) franchise with the addition of Auspex's portfolio of innovative medicines for people who live with movement disorders. The transaction has been unanimously approved by the Boards of Directors of both Teva and Auspex, and key shareholders of Auspex have entered into agreements indicating their support for the transaction.

Teva Pharmaceutical Industries is engaged in the development, manufacturing, marketing and distribution of generic, specialty, and other pharmaceutical products. The Generic Medicines segment offers a range of basic chemical entities, as well as specialized product families such as sterile products, hormones, narcotics, high-potency drugs and cytotoxic substances, in both parenteral and solid dosage forms. Co.'s specialty medicines business is focused on delivering innovative solutions to patients and providers via medicines, devices and services, includes Co.'s core therapeutic areas of the central nervous system and respiratory medicines.

Open the TEVA Page at The Online Investor »

Teva Pharmaceutical Industries is engaged in the development, manufacturing, marketing and distribution of generic, specialty, and other pharmaceutical products. The Generic Medicines segment offers a range of basic chemical entities, as well as specialized product families such as sterile products, hormones, narcotics, high-potency drugs and cytotoxic substances, in both parenteral and solid dosage forms. Co.'s specialty medicines business is focused on delivering innovative solutions to patients and providers via medicines, devices and services, includes Co.'s core therapeutic areas of the central nervous system and respiratory medicines.

Open the ASPX Page at The Online Investor »

Company Name:  Teva Pharmaceutical Industries Ltd
Website:  www.tevapharm.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding TEVA:  10
Total Market Value Held by ETFs:  $76.17M
Total Market Capitalization:  $43.46B
% of Market Cap. Held by ETFs:  0.18%
Company Name:  Auspex Pharmaceuticals Inc
Website:  www.auspexpharma.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding ASPX:  16
Total Market Value Held by ETFs:  $72.38M
Total Market Capitalization:  $2.19B
% of Market Cap. Held by ETFs:  3.31%
 

March 31, 2015    4:25 AM Eastern
Quotes delayed 20 minutes


Mega-Mergers | www.TheOnlineInvestor.com | Copyright © 1998 - 2015, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.